REVUFORJ (revumenib citrate)
ANTINEOPLASTIC - MENIN INHIBITORS · ACUTE LEUKEMIA WITH LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION ·+1
SYNDAX PHARMACE
Drug class
Antineoplastic - Menin Inhibitors
Antineoplastic menin inhibitors are a targeted therapeutic drug class designed to disrupt the interaction between the nuclear scaffold protein menin and chromatin-associated proteins, predominantly lysine methyltransferase 2A (KMT2A, formerly MLL). Read more about Antineoplastic - Menin Inhibitors
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic - Menin Inhibitors
KOMZIFTI (ziftomenib)
ANTINEOPLASTIC - MENIN INHIBITORS · ACUTE MYELOID LEUKEMIA WITH NPM1 SOMATIC MUTATION
KURA-KYOWA KIRI
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Menin Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic menin inhibitors are a targeted therapeutic drug class designed to disrupt the interaction between the nuclear scaffold protein menin and chromatin-associated proteins, predominantly lysine methyltransferase 2A (KMT2A, formerly MLL).
By blocking this specific protein-protein complex, these agents downregulate oncogenic gene transcription programs—such as HOX and MEIS1—thereby overcoming differentiation arrest and inducing apoptosis in susceptible malignant cells.
Clinically, menin inhibitors are primarily utilized in hematologic oncology to treat relapsed or refractory acute leukemias harboring specific molecular alterations, most notably KMT2A gene rearrangements or nucleophosmin 1 (NPM1) mutations.
-
nih.gov
Antineoplastic menin inhibitors are a targeted therapeutic drug class designed to disrupt the interaction between the nuclear scaffold protein menin and chromatin-associated proteins, predominantly lysine methyltransferase 2A (KMT2A, formerly MLL) By blocking this specific protein-protein complex, these agents downregulate oncogenic gene transcription programs—such as HOX and MEIS1—thereby overcoming differentiation arrest and inducing apoptosis in susceptible malignant cells Clinically, menin i...
-
cancer.gov
Antineoplastic menin inhibitors are a targeted therapeutic drug class designed to disrupt the interaction between the nuclear scaffold protein menin and chromatin-associated proteins, predominantly lysine methyltransferase 2A (KMT2A, formerly MLL)
-
nih.gov
By blocking this specific protein-protein complex, these agents downregulate oncogenic gene transcription programs—such as HOX and MEIS1—thereby overcoming differentiation arrest and inducing apoptosis in susceptible malignant cells
-
pharmacytimes.com
Clinically, menin inhibitors are primarily utilized in hematologic oncology to treat relapsed or refractory acute leukemias harboring specific molecular alterations, most notably KMT2A gene rearrangements or nucleophosmin 1 (NPM1) mutations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.